ANDA 61336, held by Glaxosmithkline. Oxacillin Sodium.
As of Nov 15, 2026, ANDA 61336 (Bactocill), held by Glaxosmithkline, was first approved by FDA on Jul 27, 1973, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 27, 1973 | Original application | Approved | None posted |
| BactocillEQ 250MG BASE · capsule;oral | Oxacillin Sodium | Discontinued |
| BactocillEQ 500MG BASE · capsule;oral | Oxacillin Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
